-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 23, Boehringer Ingelheim announced that the monoclonal antibody drug EI-001 developed in cooperation with Elixiron Immunotherapeutics has successfully completed the clinical application, and the Phase I human clinical trial will soon be launched in Australia
.
EI-001 antibodies are prepared by a single human B cells obtained technology, which is closely related to target the pathology of vitiligo, hepatitis B and the like
Boehringer Ingelheim provided Anritsu Xirong's EI-001 project with full-process services including cell line construction, production process and formulation development, stock solution and formulation cGMP production, and CMC application document writing
.
The BI-HEX® CHO-K1GS cell line and its process platform used in the EI-001 project can realize early-clinical CMC development, and seamlessly connect with the high-quality requirements of late-clinical CMC development, product launch and commercial supply